FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063556979> ?p ?o ?g. }

• W2063556979 endingPage "1256" @default.
• W2063556979 startingPage "1249" @default.
• W2063556979 abstract "Abstract Objectives Yokukansan, a traditional Japanese medicine, has been approved by the Ministry of Health, Labour, and Welfare of Japan as a remedy for neurosis, insomnia or night crying and irritability in children. It has recently been reported to improve behavioural and psychological symptoms of dementia, such as hallucinations, agitation, and aggressiveness in patients with some forms of senile dementia. Little is known about the mechanism underlying the effectiveness of yokukansan. Our aim was to clarify the involvement of yokukansan in serotonergic function in para-chloroamphetamine (PCA)-induced aggressive behaviour in rats. Methods The effect of yokukansan on social interactions, including social and aggressive behaviour, was examined in PCA-injected rats. Concentration and release level of serotonin (5-HT) in the hypothalamus were measured. Key findings PCA reduced not only the 5-HT concentration but also the high K+ -induced 5-HT release in the rat hypothalamus. Social interaction tests showed a significant decrease in social behaviour and a significant increase in aggressive behaviour in the PCA-treated rats. The decrease in social behaviour was ameliorated by the 5-HT1A agonist buspirone and further decreased by a 5-HT1A antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-hexanecarboxamide trihydrochloride (WAY-100635), whereas it was further decreased by the 5-HT2A agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI), and ameliorated by the 5-HT2A antagonist ketanserin. On the other hand, the increase in aggressive behaviour was ameliorated by buspirone but not affected by WAY-100635, whereas it was enhanced by DOI and ameliorated by ketanserin. A single injection of yokukansan ameliorated the PCA-induced decrease in social behaviour but not aggressive behaviour. Chronic treatment for 14 days with yokukansan ameliorated PCA-induced abnormal behaviour, decreased social behaviour and increased aggressive behaviour, but it did not ameliorate PCA-induced decreases in the cerebral 5-HT concentration and 5-HT release. The ameliorative effects of chronic yokukansan on behaviour were counteracted by co-administration of WAY-100635. Conclusions These results suggest that yokukansan might have two different effects: an acute effect on social behaviour and a chronic effect on aggressive behaviour. One of the mechanisms of these effects of yokukansan may be related to the agonistic effect on 5-HT1A receptors." @default.
• W2063556979 created "2016-06-24" @default.
• W2063556979 creator A5013920923 @default.
• W2063556979 creator A5016724277 @default.
• W2063556979 creator A5022369335 @default.
• W2063556979 creator A5068934687 @default.
• W2063556979 creator A5072114763 @default.
• W2063556979 creator A5088498380 @default.
• W2063556979 creator A5088840185 @default.
• W2063556979 date "2009-09-01" @default.
• W2063556979 modified "2023-10-10" @default.
• W2063556979 title "Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats" @default.
• W2063556979 cites W1688235741 @default.
• W2063556979 cites W1969759351 @default.
• W2063556979 cites W1970103266 @default.
• W2063556979 cites W1973355565 @default.
• W2063556979 cites W1974886457 @default.
• W2063556979 cites W1976871577 @default.
• W2063556979 cites W1982643751 @default.
• W2063556979 cites W1985331267 @default.
• W2063556979 cites W2004335391 @default.
• W2063556979 cites W2010261797 @default.
• W2063556979 cites W2023055592 @default.
• W2063556979 cites W2032680282 @default.
• W2063556979 cites W2039765555 @default.
• W2063556979 cites W2046974152 @default.
• W2063556979 cites W2056252291 @default.
• W2063556979 cites W2057478907 @default.
• W2063556979 cites W2059746446 @default.
• W2063556979 cites W2061996774 @default.
• W2063556979 cites W2062779672 @default.
• W2063556979 cites W2064448876 @default.
• W2063556979 cites W2064775311 @default.
• W2063556979 cites W2065171948 @default.
• W2063556979 cites W2074289934 @default.
• W2063556979 cites W2076031799 @default.
• W2063556979 cites W2076504302 @default.
• W2063556979 cites W2078046027 @default.
• W2063556979 cites W2080069537 @default.
• W2063556979 cites W2080509549 @default.
• W2063556979 cites W2081701126 @default.
• W2063556979 cites W2092881061 @default.
• W2063556979 cites W2123923673 @default.
• W2063556979 cites W2135206532 @default.
• W2063556979 cites W2135447632 @default.
• W2063556979 cites W2138889581 @default.
• W2063556979 cites W2147169882 @default.
• W2063556979 cites W2159633036 @default.
• W2063556979 cites W4211150788 @default.
• W2063556979 doi "https://doi.org/10.1211/jpp.61.09.0016" @default.
• W2063556979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19703376" @default.
• W2063556979 hasPublicationYear "2009" @default.
• W2063556979 type Work @default.
• W2063556979 sameAs 2063556979 @default.
• W2063556979 citedByCount "39" @default.
• W2063556979 countsByYear W20635569792012 @default.
• W2063556979 countsByYear W20635569792013 @default.
• W2063556979 countsByYear W20635569792014 @default.
• W2063556979 countsByYear W20635569792015 @default.
• W2063556979 countsByYear W20635569792016 @default.
• W2063556979 countsByYear W20635569792017 @default.
• W2063556979 countsByYear W20635569792018 @default.
• W2063556979 countsByYear W20635569792019 @default.
• W2063556979 countsByYear W20635569792020 @default.
• W2063556979 countsByYear W20635569792021 @default.
• W2063556979 crossrefType "journal-article" @default.
• W2063556979 hasAuthorship W2063556979A5013920923 @default.
• W2063556979 hasAuthorship W2063556979A5016724277 @default.
• W2063556979 hasAuthorship W2063556979A5022369335 @default.
• W2063556979 hasAuthorship W2063556979A5068934687 @default.
• W2063556979 hasAuthorship W2063556979A5072114763 @default.
• W2063556979 hasAuthorship W2063556979A5088498380 @default.
• W2063556979 hasAuthorship W2063556979A5088840185 @default.
• W2063556979 hasBestOaLocation W20635569791 @default.
• W2063556979 hasConcept C126322002 @default.
• W2063556979 hasConcept C15744967 @default.
• W2063556979 hasConcept C170493617 @default.
• W2063556979 hasConcept C2775864247 @default.
• W2063556979 hasConcept C2776120623 @default.
• W2063556979 hasConcept C2776885963 @default.
• W2063556979 hasConcept C2777287423 @default.
• W2063556979 hasConcept C2777785214 @default.
• W2063556979 hasConcept C2778938600 @default.
• W2063556979 hasConcept C2910298800 @default.
• W2063556979 hasConcept C37000724 @default.
• W2063556979 hasConcept C53910766 @default.
• W2063556979 hasConcept C71924100 @default.
• W2063556979 hasConcept C98274493 @default.
• W2063556979 hasConceptScore W2063556979C126322002 @default.
• W2063556979 hasConceptScore W2063556979C15744967 @default.
• W2063556979 hasConceptScore W2063556979C170493617 @default.
• W2063556979 hasConceptScore W2063556979C2775864247 @default.
• W2063556979 hasConceptScore W2063556979C2776120623 @default.
• W2063556979 hasConceptScore W2063556979C2776885963 @default.
• W2063556979 hasConceptScore W2063556979C2777287423 @default.
• W2063556979 hasConceptScore W2063556979C2777785214 @default.
• W2063556979 hasConceptScore W2063556979C2778938600 @default.
• W2063556979 hasConceptScore W2063556979C2910298800 @default.

• next